Embecta Corp. (EMBC)
5.935
+0.04
(+0.59%)
USD |
NASDAQ |
Sep 28, 16:00
5.935
0.00 (0.00%)
After-Hours: 16:16
Embecta Research and Development Expense (TTM) : 15.90M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.90M |
| March 31, 2026 | 14.10M |
| December 31, 2025 | 12.40M |
| September 30, 2025 | 21.60M |
| June 30, 2025 | 36.80M |
| March 31, 2025 | 53.40M |
| December 31, 2024 | 68.10M |
| September 30, 2024 | 78.80M |
| June 30, 2024 | 82.60M |
| March 31, 2024 | 84.80M |
| Date | Value |
|---|---|
| December 31, 2023 | 88.50M |
| September 30, 2023 | 85.20M |
| June 30, 2023 | 78.60M |
| March 31, 2023 | 70.30M |
| December 31, 2022 | 66.20M |
| September 30, 2022 | 66.00M |
| June 30, 2022 | 68.20M |
| March 31, 2022 | 69.60M |
| December 31, 2021 | 65.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Artivion, Inc. | 35.10M |
| Abbott Laboratories | 3.128B |
| AngioDynamics, Inc. | 29.45M |
| Alphatec Holdings, Inc. | 76.69M |
| AtriCure, Inc. | 94.05M |